NCT01354990已完成不适用
Sitagliptin (JANUVIA®) Post Marketing Surveillance Protocol
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,974
- 主要终点
- Number of Participants With Concomitant Therapies
研究概览
简要总结
The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes
- •Treating physician must agree to provide information regarding the participants treatment
排除标准
- 未提供
研究组 & 干预措施
Participants treated with sitagliptin
干预措施: Sitagliptin (JANUVIA®) (Drug)
结局指标
主要结局
Number of Participants With Concomitant Therapies
时间窗: Up to approximately 28 months
Number of Participants With Concomitant Conditions
时间窗: Up to approximately 28 months
Number of Participants With an Adverse Event
时间窗: Up to approximately 28 months
Age of Participants Prescribed Sitagliptin
时间窗: Up to approximately 28 months
次要结局
未报告次要终点
研究者
相似试验
终止
不适用
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsMetastatic Renal Cell CarcinomaNCT01073644Pfizer3
已完成
2 期
Sitagliptin for Reducing Inflammation and Immune ActivationHIV-1 InfectionNCT02513771Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections90
已完成
不适用
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)Complicated Skin and Skin Structure InfectionsComplicated Intra-abdominal InfectionsNCT00683332Pfizer621
已完成
不适用
Post Marketing Surveillance Study To Observe Safety And Efficacy Of SuteneGastrointestinal Stromal TumorsNCT00444795Pfizer520
撤回
不适用
A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisNCT01692457Janssen Pharmaceutica